Gain Therapeutics, Inc. - Common Stock (GANX)

Keep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down.

U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed.

The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements.

Gain Therapeutics reported positive Phase 1 results for GT-02287, showing safety and tolerability across all age groups. The company plans a Parkinson's disease trial by Q4 2024.

GANX stock results show that Gain Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Biotech stocks can be extremely challenging because it takes a long time to bring a therapy to market. Here are some biotech stocks to sell.

Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!

Arm stock is up on Friday and is preparing for a catalyst later this month when it replaces Sirius XM on the Nasdaq 100.

Gain Therapeutics stock is down on Friday after the company priced an $11 million public offering for roughly 7 million shares of GANX.